RU2016146102A - Способ лечения резистентной неходжкинской лимфомы, медуллобластомы и/или alk+ немелкоклеточного рака легкого с применением тиенотриазолодиазепиновых соединений - Google Patents
Способ лечения резистентной неходжкинской лимфомы, медуллобластомы и/или alk+ немелкоклеточного рака легкого с применением тиенотриазолодиазепиновых соединений Download PDFInfo
- Publication number
- RU2016146102A RU2016146102A RU2016146102A RU2016146102A RU2016146102A RU 2016146102 A RU2016146102 A RU 2016146102A RU 2016146102 A RU2016146102 A RU 2016146102A RU 2016146102 A RU2016146102 A RU 2016146102A RU 2016146102 A RU2016146102 A RU 2016146102A
- Authority
- RU
- Russia
- Prior art keywords
- medulloblastoma
- lymphoma
- alk
- diazepin
- thieno
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 27
- 208000002154 non-small cell lung carcinoma Diseases 0.000 title claims 10
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 title claims 10
- 150000001875 compounds Chemical class 0.000 title claims 7
- 206010025323 Lymphomas Diseases 0.000 title claims 4
- 208000000172 Medulloblastoma Diseases 0.000 claims 21
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 10
- 239000007962 solid dispersion Substances 0.000 claims 10
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 claims 9
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 8
- 229920000642 polymer Polymers 0.000 claims 5
- GNMUEVRJHCWKTO-FQEVSTJZSA-N 6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, 4-(4-chlorophenyl)-n-(4-hydroxyphenyl)-2,3,9-trimethyl-, (6s)- Chemical compound C([C@@H]1N=C(C2=C(N3C(C)=NN=C31)SC(=C2C)C)C=1C=CC(Cl)=CC=1)C(=O)NC1=CC=C(O)C=C1 GNMUEVRJHCWKTO-FQEVSTJZSA-N 0.000 claims 4
- 101150023956 ALK gene Proteins 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 210000004881 tumor cell Anatomy 0.000 claims 4
- 208000003950 B-cell lymphoma Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000009477 glass transition Effects 0.000 claims 2
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims 2
- 201000003445 large cell neuroendocrine carcinoma Diseases 0.000 claims 2
- 208000003747 lymphoid leukemia Diseases 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 206010003908 B-cell small lymphocytic lymphoma Diseases 0.000 claims 1
- 229940124291 BTK inhibitor Drugs 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 229940124292 CD20 monoclonal antibody Drugs 0.000 claims 1
- 229940126190 DNA methyltransferase inhibitor Drugs 0.000 claims 1
- 206010018691 Granuloma Diseases 0.000 claims 1
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000014579 classic medulloblastoma Diseases 0.000 claims 1
- 208000014501 desmoplastic/nodular medulloblastoma Diseases 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 239000003968 dna methyltransferase inhibitor Substances 0.000 claims 1
- 101150068690 eml4 gene Proteins 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 229940084434 fungoid Drugs 0.000 claims 1
- 230000002518 glial effect Effects 0.000 claims 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 201000005833 large cell medulloblastoma Diseases 0.000 claims 1
- 229940124302 mTOR inhibitor Drugs 0.000 claims 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 1
- 201000005776 medullomyoblastoma Diseases 0.000 claims 1
- 208000016056 medullomyoblastoma with myogenic differentiation Diseases 0.000 claims 1
- 201000005803 melanotic medulloblastoma Diseases 0.000 claims 1
- 210000003757 neuroblast Anatomy 0.000 claims 1
- 230000004031 neuronal differentiation Effects 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 201000006845 reticulosarcoma Diseases 0.000 claims 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims 1
- 238000001694 spray drying Methods 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461987813P | 2014-05-02 | 2014-05-02 | |
| US61/987,813 | 2014-05-02 | ||
| US201461990469P | 2014-05-08 | 2014-05-08 | |
| US201461990459P | 2014-05-08 | 2014-05-08 | |
| US61/990,459 | 2014-05-08 | ||
| US61/990,469 | 2014-05-08 | ||
| PCT/US2015/028798 WO2015168555A1 (en) | 2014-05-02 | 2015-05-01 | Method of treating resistant non-hodgkin lymphoma, medulloblastoma, and/or alk+non-small cell lung cancer using thienotriazolodiazepine compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2016146102A true RU2016146102A (ru) | 2018-06-05 |
| RU2016146102A3 RU2016146102A3 (cg-RX-API-DMAC7.html) | 2018-12-17 |
Family
ID=54359380
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016146102A RU2016146102A (ru) | 2014-05-02 | 2015-05-01 | Способ лечения резистентной неходжкинской лимфомы, медуллобластомы и/или alk+ немелкоклеточного рака легкого с применением тиенотриазолодиазепиновых соединений |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20170095484A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3137086A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2017514907A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20170002550A (cg-RX-API-DMAC7.html) |
| CN (1) | CN106687117A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015252940A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2947593A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2016014299A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2016146102A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015168555A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6243003B2 (ja) | 2013-03-15 | 2017-12-06 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｂｅｔタンパク質阻害剤としての三環式複素環 |
| CA2917319A1 (en) | 2013-07-08 | 2015-01-15 | Incyte Holdings Corporation | Tricyclic heterocycles as bet protein inhibitors |
| WO2015081203A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| US9315501B2 (en) | 2013-11-26 | 2016-04-19 | Incyte Corporation | Bicyclic heterocycles as BET protein inhibitors |
| US9309246B2 (en) | 2013-12-19 | 2016-04-12 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
| ES2942723T3 (es) | 2014-04-23 | 2023-06-06 | Incyte Holdings Corp | 1H-pirrolo[2,3-C]piridin-7(6H)-onas y pirazolo[3,4-C]piridin-7(6H)-onas como inhibidores de proteínas BET |
| KR20170037670A (ko) * | 2014-08-19 | 2017-04-04 | 온코에틱스 게엠베하 | 티에노트리아졸로디아제핀 화합물을 사용한 림프종의 치료 방법 |
| ES2855225T3 (es) | 2014-09-15 | 2021-09-23 | Incyte Corp | Heterociclos tricíclicos para su uso como inhibidores de proteínas BET |
| WO2016176335A1 (en) * | 2015-04-27 | 2016-11-03 | Concert Pharmaceuticals, Inc. | Deuterated otx-015 |
| TW201722966A (zh) | 2015-10-29 | 2017-07-01 | 英塞特公司 | Bet蛋白質抑制劑之非晶固體形式 |
| RS64274B1 (sr) | 2016-06-20 | 2023-07-31 | Incyte Corp | Kristalni čvrsti oblici bet inhibitora |
| CN110996913A (zh) * | 2017-06-30 | 2020-04-10 | 欧恩科斯欧公司 | 新的贝利司他口服制剂 |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2412776C (en) * | 2000-06-16 | 2011-03-15 | Mitsubishi Pharma Corporation | Compositions controlling release ph range and/or speed |
| US8476260B2 (en) * | 2007-12-28 | 2013-07-02 | Mitsubishi Tanabe Pharma Corporation | Antitumor agent |
| MX384074B (es) * | 2010-05-14 | 2025-03-12 | Dana Farber Cancer Inst Inc | Composiciones y métodos para tratar neoplasias, enfermedades inflamatorias y otros trastornos. |
| JP6265979B2 (ja) * | 2012-06-25 | 2018-01-24 | オンコエシックス ゲーエムベーハー | チエノトリアゾロジアゼピン化合物を使用するリンパ腫の治療方法 |
| HK1211209A1 (en) * | 2012-09-28 | 2016-05-20 | Oncoethix Gmbh | Pharmaceutical formulation containing thienotriazolodiazepine compounds |
| WO2015018522A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl) |
| WO2015018520A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | A bet-brd inhibitor represents a novel agent for alk positive anaplastic large cell lymphoma |
| WO2015078929A1 (en) * | 2013-11-27 | 2015-06-04 | Oncoethix Sa | Method of treating leukemia using pharmaceutical formulation containing thienotriazolodiazepine compounds |
| EP3074019A1 (en) * | 2013-11-27 | 2016-10-05 | Oncoethix GmbH | Method of treating non-small-cell lung cancer using pharmaceutical formulation containing thienotriazolodiazepine compounds |
-
2015
- 2015-05-01 MX MX2016014299A patent/MX2016014299A/es unknown
- 2015-05-01 EP EP15786309.3A patent/EP3137086A4/en not_active Withdrawn
- 2015-05-01 CA CA2947593A patent/CA2947593A1/en not_active Abandoned
- 2015-05-01 RU RU2016146102A patent/RU2016146102A/ru not_active Application Discontinuation
- 2015-05-01 US US15/308,548 patent/US20170095484A1/en not_active Abandoned
- 2015-05-01 WO PCT/US2015/028798 patent/WO2015168555A1/en not_active Ceased
- 2015-05-01 AU AU2015252940A patent/AU2015252940A1/en not_active Abandoned
- 2015-05-01 JP JP2017510449A patent/JP2017514907A/ja active Pending
- 2015-05-01 CN CN201580036829.XA patent/CN106687117A/zh active Pending
- 2015-05-01 KR KR1020167033941A patent/KR20170002550A/ko not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US20170095484A1 (en) | 2017-04-06 |
| MX2016014299A (es) | 2017-01-27 |
| CA2947593A1 (en) | 2015-11-05 |
| RU2016146102A3 (cg-RX-API-DMAC7.html) | 2018-12-17 |
| JP2017514907A (ja) | 2017-06-08 |
| EP3137086A1 (en) | 2017-03-08 |
| AU2015252940A1 (en) | 2016-11-17 |
| EP3137086A4 (en) | 2017-12-27 |
| KR20170002550A (ko) | 2017-01-06 |
| CN106687117A (zh) | 2017-05-17 |
| WO2015168555A1 (en) | 2015-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016146102A (ru) | Способ лечения резистентной неходжкинской лимфомы, медуллобластомы и/или alk+ немелкоклеточного рака легкого с применением тиенотриазолодиазепиновых соединений | |
| JP2017514907A5 (cg-RX-API-DMAC7.html) | ||
| Huddle et al. | Structure-based optimization of a novel class of aldehyde dehydrogenase 1A (ALDH1A) subfamily-selective inhibitors as potential adjuncts to ovarian cancer chemotherapy | |
| Czodrowski et al. | Structure-based optimization of potent, selective, and orally bioavailable CDK8 inhibitors discovered by high-throughput screening | |
| Sumi et al. | Chemoproteomics reveals novel protein and lipid kinase targets of clinical CDK4/6 inhibitors in lung cancer | |
| Duffey et al. | Discovery of a potent and orally bioavailable benzolactam-derived inhibitor of Polo-like kinase 1 (MLN0905) | |
| ES2586588T3 (es) | Derivados tricíclicos, procedimiento para su preparación y su uso como inhibidores de quinasa | |
| Cheung et al. | Aurora kinase inhibitor patents and agents in clinical testing: an update (2011–2013) | |
| RU2591191C2 (ru) | Трициклические пирроло производные, способ их получения и их применение в качестве ингибиторов киназы | |
| US20220304984A1 (en) | Amino acid transport inhibitors and the uses thereof | |
| Lu et al. | Targeting translation: eIF4E as an emerging anticancer drug target | |
| JP2016529246A5 (cg-RX-API-DMAC7.html) | ||
| RU2017100921A (ru) | Способ лечения немелкоклеточного рака легких и/или мелкоклеточного рака легких с применением соединений тиенотриазолодиазепина | |
| JP5852678B2 (ja) | 抗腫瘍剤の効果増強剤 | |
| Daniele et al. | Dual inhibition of PDK1 and Aurora Kinase A: an effective strategy to induce differentiation and apoptosis of human glioblastoma multiforme stem cells | |
| Ma et al. | Discovery of selective small-molecule inhibitors for the ENL YEATS domain | |
| AR063343A1 (es) | Compuestos para modular c-kit y receptores de pdgfr | |
| RU2016147946A (ru) | Способ лечения трижды негативного рака молочной железы с использованием тиенотриазолодиазепиновых соединений | |
| RU2015115634A (ru) | Фармацевтический состав, содержащий соединения тиенотриазолодиазепина | |
| BR112012029057A2 (pt) | composições e métodos de tratamento de leucemia | |
| JP2017529332A5 (cg-RX-API-DMAC7.html) | ||
| Dong et al. | Discovery of potent and wild-type-sparing fourth-generation EGFR inhibitors for treatment of osimertinib-resistance NSCLC | |
| JP2014518544A5 (cg-RX-API-DMAC7.html) | ||
| JP2017517579A5 (cg-RX-API-DMAC7.html) | ||
| Xu et al. | Design, synthesis, and biological evaluation of 2-oxo-3, 4-dihydropyrimido [4, 5-d] pyrimidinyl derivatives as new irreversible epidermal growth factor receptor inhibitors with improved pharmacokinetic properties |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20190514 |